Navigation Links
Gains from a Growing Patient Pool for Cardiac Rhythm Management Devices Offset by Lower Product Pricing, Observes Frost & Sullivan

LONDON, Feb. 7, 2013 /PRNewswire/ -- The rising incidence of lifestyle diseases such as diabetes and obesity, an ageing population and the prevalence of cardiovascular diseases such as arrhythmias, heart failure and atrial fibrillation, have expanded the patient pool for cardiac rhythm management (CRM) devices in both Europe and the United States.

The larger market, however, does not translate to higher revenues, as there is considerable pressure on manufacturers to reduce the cost of all pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) devices.

New analysis from Frost & Sullivan (, Western European and U.S. Cardiac Rhythm Management Devices Market, finds that the European and U.S. markets together earned revenues of $8.69 billion in 2011 and estimates this to reach $8.72 million in 2016.

"CRM device manufacturers have managed to stay afloat in this market through continuous product upgrades and technological advancements," says Frost & Sullivan Research Analyst Brahadeesh Chandrasekaran. "Companies that launch an innovative product that addresses end-user concerns will gain significant first-mover advantage."

A segment that has benefited substantially from technology improvements, especially in imaging techniques, is catheter ablation. It is one of the fastest growing segments in the CRM devices market and is considered a safe and effective treatment method for most arrhythmias.

About 25% of electrophysiologists spend their time performing catheter ablation. While this bodes well for the catheter ablation segment, it lowers the adoption of other cardiac devices such as ICDs.

Between Western Europe and the United States, the latter is the larger CRM market in terms of revenue and unit shipments. Overall, both these regions are the largest sales and revenue contributors to the global market.

"However, as the CRM markets in both these regions are consolidated, it is difficult for new or small companies to compete effectively," notes Chandrasekaran. "International companies can penetrate the European CRM market by establishing partnerships and alliances to distribute or increase their product lines."

Healthcare settings are looking for one-stop shops for all their required products and services. Most companies are responding to this demand to gain new customers or retain shares in an intensely competitive market.

If you are interested in more information on this research, please send an email to Anna Zanchi , Corporate Communications, at

Western European and U.S. Cardiac Rhythm Management Devices Market is part of the Medical Devices Growth Partnership Services program, which also includes research in the following markets: U.S. and Western European Cardiac Rhythm Management, Western European Dental Implants Market, Medical Device Industry – Recovering from Recession, European Orthopaedic Devices Market Outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
2. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
3. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
4. Suture Express Files Antitrust Lawsuit Against Cardinal Health and Owens & Minor
5. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
6. Robbins Umeda LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Abiomed, Inc.
7. Modified Citrus Pectin Protects Against Vascular Hardening
8. Novo Nordisk Supports Four San Francisco-based Organizations In Fight Against Diabetes
9. The Princess Margaret BMT Program Chooses Remedy Informatics Blood and Marrow Transplant & Cell Therapy Solutions to Power their fight Against Cancer
10. Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
11. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
Post Your Comments:
(Date:10/12/2015)... Elbit Imaging Ltd. ("EI" or the ... board of directors approved a program to repurchase up to ... H Notes and Series I Notes, which are traded on ... the Company will have a significant preference to the purchase ... to time in the open market on the Tel Aviv ...
(Date:10/12/2015)... ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Industry Trends, Technologies, Participants, and Environment" ... ) has announced the addition of ... Companion Diagnostic Market to 2019 - Strategic ...
(Date:10/12/2015)... , October 12, 2015 ... interest from pharmaceutical companies as they look to ... others appear in a new report by  visiongain ... market gains much interest from pharmaceutical companies as ... finding and many others appear in a new ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... In an ongoing effort to provide the ... Texas, child development and pediatric therapy center, is working with TRICARE to emphasize ... options for receiving this kind of care for affected children. Because of concerns ...
(Date:10/13/2015)... ... October 13, 2015 , ... Bambeco, Inc., the premier brand ... announced it closed on a $20.5 million funding round led by ABS Capital ... the Company’s continued rapid growth and expansion, broaden the Company’s product offerings, and ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... show this coming October in Toronto, an exhibition featuring the newest products and ... from, Curly Hair Solutions® couldn’t be more excited to unveil their recent partnership ...
(Date:10/13/2015)... ... October 13, 2015 , ... This ... commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a significant women's health ... Vancouver, BC, Canada. , In a presentation entitled: "The Microbiome and ...
Breaking Medicine News(10 mins):